Medicine and Dentistry
Idiopathic Pulmonary Fibrosis
100%
Patient
72%
Interstitial Lung Disease
60%
Diagnosis
50%
COVID-19
36%
Therapeutic Procedure
31%
Lung
27%
Combination Therapy
26%
Pulmonary Fibrosis
26%
Inpatient
25%
Diseases
25%
Nintedanib
21%
Placebo
15%
Hypersensitivity Pneumonitis
14%
Usual Interstitial Pneumonia
12%
Forced Vital Capacity
12%
Chemotherapeutic Agent
11%
Drug
11%
Fibrosis
10%
Silo-Filler's Disease
9%
Deterioration
9%
Echography
8%
Lung Biopsy
8%
Disease Exacerbation
8%
Idiopathic Interstitial Pneumonia
7%
Fibroblast
7%
Pirfenidone
7%
Amaurosis
6%
Development
6%
Severe Acute Respiratory Syndrome Coronavirus 2
6%
Fine-Needle Aspiration
6%
Evaluation Study
5%
Sarcoidosis
5%
Clinician
5%
Biological Marker
5%
Comprehension
5%
Pneumonia
5%
Infection
5%
Prevalence
5%
High-Resolution Computed Tomography
5%
Respiratory Medicine
5%
Muscle Function
5%
Pharmacology, Toxicology and Pharmaceutical Science
Fibrosing Alveolitis
72%
Nintedanib
49%
Placebo
24%
Interstitial Lung Disease
18%
Drug
17%
Pirfenidone
16%
Lung Fibrosis
14%
Adverse Event
13%
Diseases
12%
Deterioration
11%
Clinical Trial
10%
Asthma
10%
Blindness
8%
Tolerability
7%
Pamrevlumab
7%
Fibrosis
5%
Lung Disease
5%
Nursing and Health Professions
Patient
18%
Interstitial Lung Disease
6%
Fatigue
5%
Diagnosis
5%
Fibrosing Alveolitis
5%
